|
Select from the list below to view the abstracts from the 2002 workshop in Athens. The abstracts are in PDF format and are organized by topic. Corresponding papers from this conference were published in a special edition of Seminars in Oncology in April of 2003. Abstracts can also be accessed by following the links in the Athens program of events section.
The browser you are using will not work with the contents of this page, we recommend that you update to a newer browser or check to make sure that JavaScript is enabled.
Genetic Basis and Pathogenesis
Clonotypic IgH VDJ Sequences in Waldenstrom's Macroglobulinemia Indicate its Origin from an Unusual Memory B Cell Subset. Linda Pilarski, Jitra Krangkum, Brian Taylor, Michael Mant, Steven Treon, and Andrew Belch.
Clonal Origins of Waldenstrom's Macroglobulinemia. S.S. Sahota, F. Forconi, C.H. Ottensmeier, T.J. Hamblin, and F.K. Stevenson
Gene Expression Profiling of CD19, CD20, and CD138-Enriched Cells from Waldenstrom's Macroglobulinemia (WM) Reveals Distinct Classes and Novel WM-Specific Genes. John Shaughnessy, Fenghuang Zahn, Erming tian, Madhumita Santra, Hongwei Xu, Ruston Smith, and Bart Barlogie.
Family Studies in Waldenstrom's Macroglobulinemia (WM). ML McMaster.
Molecular Cytogenetics of Waldenstrom's Macroglobulinemia (WM) Indicate Lack of 14q32 Translocations, Genomic Stability, and Frequent 6Q Deletions.Roelandt Schop, Michael Kuehl, Scott Van Wier, Gregory Ahmann, Tammy Price-Troska, Richard Bailey, Syed Jalal, Ying Qi, Robert Kyle, Philip Griepp, Rafael Fonseca.
14q32 Traslocations Discriminate IgM MM from WM. H Avet-Loiseau.
Proteomic Analyses in Waldenstrom's Macroglobulinemia. N. Mitsiades, C.S. Mitsiades, K.C. Anderson, S.P. Treon.
Dysregulation of Apoptosis in Waldenstrom's Macroglobulinemia does not Involve NFkB Activation. Derek Leitch and Roger Owen.
Overexpression and Novel Splice Variants of Hyaluronan Synthatses In Waldenstrom's Macroglobulinemia. S. Adamia, M. Crainie, J. Krangkum, AR. Belch, and LM Pilarski.
Monoclonal Gammopathies
Long-term Follow-Up of IgM Monoclonal Gammopathy of Undetermined Signigicance (MGUS). R.A. Kyle, T.M. Therneau, S.V. Rajkumar, J.R. Offord, D.R. Larson, M.F. Plevak, L.J. Melton III.
Analysis of 452 Patients with Asymptomatic IgM Monoclonal Gammopathy: A Prognostic Index to Predict Evolution to Symptomatic Waldenstrom's Macroglobulinemia. E. Morra, C. Cesana, C. Klersy, M. Varettoni, L. Cavannna, B. Canesi, E. Tresoli, L. Barbarano, M Lazzarino.
Malignant Transfomation In IgM Monoclonal Gammopath of Undertermined Significance (MGUS). S. Montoto, J. Bladé, M. Rozman, L. Rosinol, B. Nadal, E. Giné, M. Aymerich, J. Esteve, E. Monserrat.
Defining Waldenstrom's Macroglobulinemia
Despite Apparent Morphologic and Immunophenotypic Heterogeneity, Waldenstroms Macroglobulinemia is Consistently Compased of C alls Along a Morphologic Continuum of Small Lymphocytes, Plasmacytoid Lymphocytes, and Plasma Cells. Ellen Remstein, Paul Krtin, Robert Kyle, Janice Hodenfield, Curtis Hason.
Immunophenotypic Analysis of Waldenstrom's Macroglobulinemia. J.F. San Miguel, M.B. Vidriales, G. Mateo, E. Ocio, F. Sánchez, L. Escribano, A. Barez, M.J. Moro, J. Hernández, C.Aguilera, R. Cuello, R. Lopez, J. Portero, A. Orfao.
Developing Diagnostic Criteria In Waldenstrom's Macroglobulinemia. Roger Owen.
Differential Diagnosis of Waldenstrom's Macroglobulinemia (WM) from Other B Chronic Lymphoproliferative Disorders (LPDS). GA Pangalis, M-C Kyrtsonis, TP Vassilakopoulos, MP Siakantaris, FN Kontopidou, C Kittas, MK Angelopoulou.
Asmptomatic Waldenstrom's Disease. R. Alexanian, D. Weber, K. Delasalle, F. Cabanillas, M. Dimopoulos.
Appropriateness of applying the response criteria for multiple myeloma (MM) to Waldenstrom's macroglobulinemia (WM). Joan Bladé and Silvia Montoto.
Prognostic Markers Waldenstrom's Macroglobulinemia
Prognostic Factors in Waldenstrom's Macroglobulinemia. Merlini G, Baldini L, Broglia C, Goldaniga M, Palladini G, Gobbi PG.
Prognostic Factors in Waldenstrom's Macroglobulinemia: Description of the Complications During the Evolution. Laure Stalnikiewicz, Laurence Detourmignies, Pierre Morel.
Fludarabine for Waldenstrom's Macroglobulinemia: Update of Southwest Oncology Group S9003 trial. Bart Barlogie, Joth Jacobson, Madhav Dhodapkar, Robert Kyle, Morie Gertz, David Roodman, John Crowley.
Paterns of Clinical Presentation, treatment, and Outcome in Patients with Waldenstrom's Macroglobulinemia: a Two Institutional Study. Bjorkholm M, Johansson E, Papamichael D, Celsing F, Matthews J, Lister TA, Rohatiner AZS.
Smouldering Waldenstrom's Macroglobulinemia: Factors Predicting Evolution To Symptomatic Disease. Clara Cesana, Sara Miqueleiz, Patrizia Bernuzzi, Elisabetta Tresoldi, Valentina Rossi, Giovanna D’Avanzo, Davide Filippini, Enrica Morra.
Therapeutics in WM: Alkylator agents and nucleoside analogues
Nucleoside analog therapy in Waldenstrom's Macroglobulinemia (WM). V. Leblond.
2-Chlorodeoxydenosine (2-CdA) Alone or in Combination for Waldesntrom’s Macroglobulinemia (WM). DM Weber, MA Dimopoulos, K Delasalle, K Rankin, M Gavino, R Alexanian.
Cladribine (2-CdA) alone or in combination with Mitoxantrone in the treatment of Waldenstrom's macroglobulinemia and first results with Bendamustine plus Rituximab: Results of prospective multicenter studies of a German lymphoma study group. Mathias Rummel and Paris Mitrou. ****
Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's Macroglobulinemia, and mantle-cell lymphoma. JM Foran, AZ Rohatiner, B Coiffier, T Barbui, SA Johnson, W Hiddemann, JA Radford, AJ Norton, SM Tollerfield, MP Wilson, TA Lister.
Therapeutics in WM: Monoclonal Antibodies
Combination Therapy with Rituximab and fludarabine is highly active in Waldenstrom's Macroglobulinemia. Steven Treon, Parveen Wasi, Christos Emmanouilides, Staley Frankel, Eva Kimby, Andrew Lister, Pierre Morel, Abigail Kelliher, Andrew Branagan, Frederick Preffer, Kenneth Anderson.
Pre-therapy serum IgM levels predict clinical response to extended rituximab in Waldenstrom's macroglobulinemia. Steven Treon, Christos Emmanouilides, Eva Kimby, Andrew Branagan, Constatine Mitsiades, Kenneth Anderson, and Stanley Frankel.
Polymorphisma in Fc gamma RIIIa (CD16) receptor expression are associated with clinical response to Ritucimab in Waldenstrom's macroglobulinemia. Steven Treon, Edward Fos, Mark Hansen, Sigitas Verselis, Andrew Branagan, Nikolaos Touroutoglou, David Maloney, Stanely Frankel, Menneth Anderson, Christos Emmmanouilides, and Eva Kimby.
Enhancing Rituximab Efficacy with IFN-Alfa. Eva Kimby.
CD22 as a target for pssive immubotherapy. Alessandra Cesano.
In Vivo efficacy of anti-CD40 antibody for human B- cell lineage hematological malignancies. Iqbal Grewal.
Campath-1H for treatment of Waldenstrom's Maccroglobulinemia (WM). Peggy Crowley-Norwick, Fred Preffer, Abby Kelliher, and Steven treon.
New Monoclonal Antibodies for the Treatment of Waldnestrom’s macroglobulinemmia and Chronic lymphocytic leukemia. John Byrd.
Phase I study of Zevalin (Ibritumomab Tiuxetan) in Waldenstrom's Macroglobulinemia (Lymphoplasmacytic lymphoma).C. Emmmanouilidies, P. Multani, S. Treon.
Therapeutics in WM: Thalidomide
Bone Marrow angiogenesis in Waldenstroms Macroglobulinemia (WM). S. Vincent Rajkumar, Suzanne Hayman, and Philip Greipp.
Thalidomide-based treatment for Waldenstrom's macroglobulinemia. M.A. Dimopoulos, A. Zomas, K. Tsatalas, G Hamilos, E. Efstathiou.
Biaxin, low dose thalidomide, and dexamethasone (BLT-D) are highly active in Waldenstrom's macroglobulinemia. Morton Coleman.
Potential New Pharmaceutics for the Treatment of Waldenstrom's Macroglobulinemia. JB Zeldis.
Rituximab Induced antibody Dependent Cell mediated Cytotoxicity (ADCC) is enhanced by thalidomide and its analogue Revimid. Toshiaki Hayashi, Kenneth Anderson, Steven Treon.
Therapeutics in WM: Transplant Therapy
High dose chemotherapy with stem cell transplantation for Waldenstrom's Macroglobulinemia (WM). Nikhil Munshi and Bart Barlogie.
Autologous stem cell transplant in WM. Athanasios Anagnostopoulos.
Transplantation in Waldenstrom's Macroglobulinemia. The French experience. O. Tournilhac, V. Leblond, R Tabrizi, R Gressin, P Colomba, N Milpied, B Cain, M Divine, B Dreyfus, JY Cahn, B Pignon, B Desabiens, JF Perrier, JO Bay, R Travade.
Allogeneic stem cell transplant in WM. Sergio Giralt.
The use of non-Myeloablative Allogeneic Hematopoitic cell transplantation for patients with refractory Waldenstrom's Macroglobulinemia – Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. David Maloney, Brenda Sandmaier, Make Maris, and Rainer Storb.
|
